Reações de hipersensibilidade a vacinas / Hypersensitivity reactions to vaccines

O desenvolvimento e a ampliação do uso das vacinas durante décadas contribuíram para o controle e erradicação de doenças infecciosas, causando um grande impacto na saúde pública no mundo. A análise de segurança das vacinas percorre criteriosos processos e fases dos estudos clínicos, um dos pilares essenciais para aprovação regulatória e utilização do produto na população. O evento supostamente atribuído à vacinação e imunização (ESAVI), terminologia atual, é definido como qualquer ocorrência médica indesejada após a vacinação que possui, ou não, uma relação causal com o uso de uma vacina ou outro imunobiológico. Cabe ressaltar que eventos adversos mais raros ou inesperados, incluindo os eventos de hipersensibilidade, poderão ocorrer na fase pós-comercialização, quando as vacinas são aplicadas em milhões de pessoas. Neste artigo, serão discutidos os principais aspectos relacionados aos eventos adversos de hipersensibilidade pós-vacinais de interesse do especialista, e os desafios frente ao reconhecimento do agente causal e conduta a ser adotada. Além disso, serão revisados os potenciais alérgenos presentes nas vacinas de uso rotineiro para auxiliar o profissional de saúde na identificação de pacientes com potencial de risco de ESAVI por tais componentes. A atualização do conhecimento acerca da segurança e dos benefícios das vacinas pelos profissionais de saúde, sobretudo em populações especiais, contribui para condutas em imunização mais apropriadas, reduzindo o risco de exposição a um possível alérgeno em pessoas comprovadamente alérgicas às vacinas ou a alguns dos seus componentes, além de evitar contraindicações desnecessárias em eventos coincidentes ou não graves.

The expansion of vaccine use and development in recent decades has contributed to the control and eradication of infectious diseases, causing a major impact on public health worldwide. Vaccine safety analysis, which involves careful processes and clinical study, is one of the essential pillars of regulatory approval and use in the population. In current terminology, events supposedly attributable to vaccination and immunization (ESAVI) are defined as any unwanted medical occurrence after vaccination that may or may not have a causal relationship with vaccines or other immunobiologicals. It is noteworthy that rare or unexpected adverse events, including hypersensitivity, can occur during the post-marketing phase, when vaccines are administered to millions of people. In this article, we will discuss the main aspects of post-vaccine hypersensitivity events of interest to specialists and challenges to recognizing the causal agent and appropriate clinical practice. Potential allergens in routine vaccines will also be reviewed to help health professionals identify patients with a potential risk of ESAVI due to such components. Updating health professionals' knowledge about the safety and benefits of vaccines, particularly in special populations, can contribute to more appropriate clinical practice regarding immunization, reducing the risk of exposure to possible allergens in people with allergies to vaccines or their components, avoiding unnecessary contraindications in coincidental or non-serious events.

Vacunación antigripal en personal de salud que trabaja con niños en un prestador privado de salud: años 2019 y 2020 / Flu vaccine administered to health care personnel working with children at a private health provider (2019-2020) / Vacina contra influenza administrada a profissionais de saúde que trabalham com crianças numa operadora de saúde privada (2019-2020)

Introducción: la infección por el virus de la gripe genera morbimortalidad. El personal de salud es uno de los grupos prioritarios para ser vacunado. Objetivo: conocer cobertura vacunal contra la gripe del personal de salud que trabaja con niños en CASMU en 2019 y 2020, y las razones por las que se vacunaron o no. Material y método: estudio observacional, descriptivo, transversal. Recolección de datos en 2020 a través de un cuestionario anónimo. Se registraron las siguientes variables: edad, lugar de trabajo (urgencias, internación o policlínica), función, riesgo de enfermedad grave, aplicación o no de vacuna en 2019 y en 2020, y motivos de vacunación o de no vacunación. Resultados: completaron la encuesta 204 trabajadores. En 2019, se vacunó el 73 % y, en 2020, el 77,5 % (p >0,05). El personal de salud de urgencias de Montevideo presentó mayor vacunación (en 2019, el 90,7 %; en 2020, el 93 %), seguido por el personal de salud de urgencias de Ciudad de la Costa e internación. Según la ocupación, para los médicos se registró una vacunación mayor al 95 % (2019 y 2020); para las licenciadas y auxiliares de enfermería, el 68,6 % en 2019 y el 75,7 % en 2020; para el personal no clínico, el 33 % en 2019 y el 41 % en 2020. El aumento de vacunados en 2020 no fue significativo en ninguna de las ocupaciones. El 21 % de los encuestados presentaba riesgo de enfermedad grave; el 65 % de estos se vacunó en 2019 y el 74,4 % en 2020. La totalidad de las embarazadas de la muestra se vacunó. Motivos más frecuentes mencionados de vacunación (2019 y 2020): prevención (50,5 %) y ser personal de salud (36 %). El de quienes no se vacunaron fue "Nunca enfermo" (19 %). Quienes no se administraron la vacuna en 2019, pero sí en 2020, mencionaron más frecuentemente la pandemia como motivo. Conclusión: en CASMU, el porcentaje de trabajadores de la salud en contacto con niños que se adhirió a la vacunación antigripal en 2019 y 2020 fue mayor al 70 %. No se registró aumento significativo por la pandemia. Se debe mejorar la cobertura en policlínicas y del personal de salud no médico, en particular del personal de salud con factores de riesgo de enfermedad grave.

Introduction: the influenza virus infection causes morbidity and mortality. Health care personnel (HCP) is one of the priority groups to be vaccinated. Objective: to learn about HCP's vaccination coverage against influenza of those workers working with children at CASMU in 2019 and 2020, and the reasons why they received vaccination or did not. Material and Methods: observational, descriptive, crosssectional study. Data collection in 2020: anon ymous survey. Variables: age, place of work (emer gency, hospital or clinic), function, risk of serious illness, vaccination received (or not received) in 2019 and 2020 and reasons. Results: 204 workers completed the survey; influenza vaccination: 73% in 2019 and 77.5% in 2020 (p>0.05). Montevideo's Emergency Department presented the highest level of vaccination and hospitalization (2019-90.7%; 2020-93%) followed by the Ciudad de la Costa's Emergency Department. By occupational level: doctors: vaccination> 95% (2019 and 2020); graduates and nursing assistants: 2019-68.6%; 2020- 75.7%; administrative, kitchen, cleaning and gate house staff: 2019-33%, 2020-41%. The increase in vaccinated personnel in 2020 was not significant for any of the occupations. 21% of those surveyed had a risk of serious illness; 65% were vaccinated in 2019 and 74.4% in 2020. All the sampled pregnant women were vaccinated. The most frequent reasons mentioned for vaccination (2019 and 2020): "prevention" (50.5%), being PS (36%). Those who were not vaccinated stated that were "never ill" (19%). Those who had not received the vaccine in 2019, but received in 2020, mostly mentioned the "pandemic" as a reason. Conclusion: in CASMU, the percentage of health workers in contact with children who adhered to the flu vaccination in 2019 and 2020 was higher than 70%. There was no significant increase after to the pandemic. Coverage in polyclinics and nonmedical HCP, in particular those HCP with risk factors for serious diseases, should be improved.

Introdução: a infecção pelo vírus influenza gera morbimortalidade. O pessoal de saúde (PS) é um dos grupos prioritários a ser vacinado. Objetivo: conhecer a cobertura vacinal contra influenza do PS que atende crianças no CASMU em 2019 e 2020, e os motivos pelos quais foram vacinados ou não. Material e Métodos: estudo observacional, descritivo e transversal. Coleta de dados em 2020: questionário anônimo. Variáveis: idade, local de trabalho (emergência, internação ou policlínica), função, anos de trabalho, risco de doença grave, aplicação ou não da vacinação em 2019 e 2020 e motivos. Resultados: 204 trabalhadores responderam à pesquisa; vacinação contra influenza: 73% em 2019 e 77,5% em 2020 (p> 0,05). O pronto socorro de Montevidéu apresentou o maior nível de vacinação (2019-90,7%; 2020-93%) seguido pelo pronto socorro de Ciudad de la Costa e internação. Ocupação: médicos: vacinação> 95% (2019 e 2020); graduados e auxiliares de enfermagem: 2019-68,6%; 2020-75,7%; Pessoal administrativo, cozinha, limpeza e porteiros: 2019-33%, 2020-41%. O aumento de vacinados em 2020 não foi significativo em nenhuma das ocupações. 21% dos entrevistados corriam risco de doenças graves; 65% deles foram vacinados em 2019 e 74,4% em 2020. Todas as gestantes da amostra foram vacinadas. Motivos mais citados para a vacinação (2019 e 2020): "prevenção" (50,5%), sendo PS (36%). Aqueles que não foram vacinados disseram que eles "nunca ficavam doentes" (19%). Os que não receberam a vacina em 2019, mas sim em 2020, citaram com mais frequência a "pandemia" como motivo. Conclusão: no CASMU, a percentagem de profissionais de saúde em contato com crianças que aderiram à vacinação contra gripe em 2019 e 2020 foi superior a 70%. Não houve aumento significativo após a pandemia. A cobertura em policlínicas e profissionais de saúde não médicos e, em particular, profissionais de saúde com fatores de risco para doenças graves, deve ser melhorada.

Impact of H5N8 duck and chicken viral isolates on the immunological profile of vaccinated specific pathogen free chickens

Nowadays, there is a global concern about outbreaks caused by the highly pathogenic avian influenza virus H5N8 clade 2.3.4.4 which caused devastating losses in the poultry industry sector. This clade was subdivided into two waves: clade 2.3.4.4A from 2014 to 2015 and clade 2.3.4.4b from 2016 until now. In this literature we aimed to evaluate the efficacy of recently used inactivated commercial avian influenza vaccines against two new Egyptian highly pathogenic avian influenza virus H5N8 isolates of clade 2.3.4.4b, A/chicken/Egypt/1526v/2020/H5N8 (H5N8-CH) and A/Duck/Egypt/Qalubia321/2021 (H5N8-D). Three-week-old specific pathogen free chickens were vaccinated with eight types of the most recently used inactivated avian influenza vaccines containing homologous and heterologous virus to the circulating H5N8 isolates. All specific pathogen free chicken groups were bled weekly post vaccination for antibody analysis using two H5N8 isolates of chicken and duck origin as antigen in hemagglutination inhibition test. Also, all vaccinated chicken groups were challenged 4 weeks post vaccination against the H5N8 duck isolate with a dose of 109 EID50/0.1 mL per chicken to measure the protection percentage of the commercial vaccines used. The results showed that vaccines with homologous and heterologous virus showed variable degrees of accepted protection percentage ranged from 90percent to 100percent, thus it was concluded that not only the genetic and antigenic match of the vaccine strains with the circulating highly pathogenic avian influenza viruses influences vaccine efficiency; other factors, such as manufacturing procedures, adjuvant, antigen content, vaccine dose and administration factors could affect vaccine efficacy, therefore, further vaccine development studies are needed to improve the percentage of protection and prevention of viral shedding against local highly pathogenic avian influenza H5 viruses in Egypt(AU)

En la actualidad, existe una preocupación mundial por los brotes causados por el virus de la gripe aviar altamente patógena H5N8 clado 2.3.4.4 que causó pérdidas devastadoras en el sector de la industria avícola. Este clado se subdividió en dos oleadas: clado 2.3.4.4A de 2014 a 2015 y clado 2.3.4.4b de 2016 hasta ahora. En el presente trabajo, dos aislamientos egipcios de la gripe aviar altamente patógena H5N8 del clado 2.3.4.4b, A/chicken/Egypt/1526v/2020/H5N8 (H5N8_CH) y A/Duck/Egypt/Qalubia321/2021 (H5N8_D), se utilizaron para evaluar la eficacia de vacunas comerciales inactivadas contra la gripe aviar de reciente utilización. Pollos libres de patógenos específicos de tres semanas de edad fueron vacunados con ocho vacunas inactivadas contra la influenza aviar, de uso reciente, que contenían virus homólogos y heterólogos a los aislamientos circulantes de H5N8. Todos los grupos de pollos libres de patógenos específicos fueron sangrados semanalmente tras la vacunación para el análisis de anticuerpos; dos virus H5N8 aislados de pollo y pato se utilizaron como antígeno en la prueba de inhibición de la hemaglutinación. Además, todos los grupos de pollos vacunados fueron retados 4 semanas después de la vacunación con el virus H5N8 aislado de pato, con una dosis de 109 EID50/0,1 mL por pollo, para medir el porcentaje de protección de las vacunas comerciales utilizadas. Los resultados mostraron que las vacunas con virus homólogos y heterólogos presentaron grados variables de aceptada protección, la que osciló entre el 90 por ciento y el 100 por ciento, por lo que se concluyó que no sólo la coincidencia genética y antigénica de las cepas vacunales con los virus circulantes de la influenza aviar altamente patógena influye en la eficacia de la vacuna; otros factores, como los procedimientos de fabricación, el adyuvante, el contenido en antígenos, la dosis de la vacuna y los factores de administración podrían afectar a la eficacia de la vacuna, por lo que es necesario seguir estudiando el desarrollo de vacunas para mejorar la protección y la prevención de la excreción viral contra los virus H5 de la influenza aviar altamente patógena locales en Egipto(AU)

Efficacy of some avian influenza H5 vaccines against local highly pathogenic avian influenza viruses subtype H5N8 isolated in 2018 and 2020 in Egypt

Commercial inactivated avian influenza H5 vaccine is used as an essential control strategy for avian influenza disease in Egypt. Since the initial outbreaks of highly pathogenic avian influenza H5N8, the virus has diverged with new genotypes and variant viruses continuing to emerge which mainly stand behind vaccination failure. In the present work, four different commercial avian influenza vaccines were inoculated in specific pathogenic free chickens for assessing its efficacy against local highly pathogenic avian influenza H5N8 virus isolated in 2018 and 2020. Two hundred and forty specific pathogenic free chickens were clustered into four groups; each group was inoculated with the corresponding vaccine (60 specific pathogenic free chickens/vaccine). Sixty specific pathogenic free chicks were kept as control unvaccinated group. Sera collected from vaccinated chicken groups at 3rd and 4th week post vaccination were examined for calculating neutralizing antibodies using heterologous highly pathogenic avian influenza H5N8 2018 and 2020. At 4th week post vaccination, vaccinated chickens were challenged; moreover, oropharyngeal swabs were collected from challenged vaccinated chickens to calculate the viral shedding. Our findings revealed the groups vaccinated with vaccine code no 1 and 2 that contains two vaccine strains (H5N1 and H5N8) of local origin exhibited the highest hemagglutination inhibition titer, protection (percent) and reduction in viral shedding titer when examined by highly pathogenic avian influenza H5N8 2018 while, vaccine code no 3 induced lower antibody response, protection (percent) and reduction in viral shedding, but still within satisfactory level when compared to previous groups. When highly pathogenic avian influenza H5N8 2020 was used, it was found the seroconversion rate, protection (percent) and mean titer of reduction of viral shedding decreased in comparison to those recorded for highly pathogenic avian influenza H5N8 2018. Vaccine code no 4 was impotent to either highly pathogenic avian influenza 2018 or 2020. Accordingly, it was recommended to update vaccine strain according to epidemiological condition and used the predominant circulating strain isolate in challenge test(AU)

La vacuna comercial inactivada H5 se utiliza como estrategia esencial de control de la enfermedad de la gripe aviar en Egipto. Desde los brotes iniciales de la gripe aviar altamente patógena H5N8, el virus ha variado al aparecer continuamente nuevos genotipos y variantes virales, que son los principales responsables del fracaso de la vacunación. En el presente trabajo, cuatro vacunas comerciales diferentes contra la gripe aviar se inocularon en pollos libres de patógenos específicos para evaluar su eficacia contra cepas del virus local de la gripe aviar altamente patógeno H5N8 aisladas en 2018 y 2020. Se agruparon 240 pollos pollos libres de patógenos específicos en cuatro grupos, cada uno fue inoculado con la vacuna correspondiente (60 pollos pollos libres de patógenos específicos/vacuna). Sesenta pollos SPF se mantuvieron como grupo control sin vacunar. Los sueros de los pollos vacunados recogidos en la 3ª y 4ª semana después de la vacunación se examinaron para calcular los anticuerpos neutralizantes contra la gripe aviar heteróloga H5N8 2018 y 2020. En la cuarta semana después de la vacunación, los pollos vacunados fueron retados; además, se recogieron hisopados orofaríngeos de los pollos vacunados retados para calcular la diseminación viral. Nuestros resultados revelaron que los grupos vacunados con las vacunas con códigos nº 1 y 2, que contienen dos cepas vacunales (H5N1 y H5N8) de origen local, mostraron el mayor título de inhibición de la hemaglutinación, protección (por ciento) y reducción del título de excreción viral cuando se evaluaron contra la gripe aviar altamente patógena H5N8 2018, mientras que la vacuna con código nº 3 indujo menor respuesta de anticuerpos, protección (por ciento) y reducción de la excreción viral, pero todavía dentro de un nivel satisfactorio en comparación con los grupos anteriores. Al utilizar la vacuna contra la gripe aviar altamente patógena H5N8 2020, se observó que la tasa de seronconversión, la protección (por ciento) y el título medio de reducción de la excreción viral disminuyeron en comparación con los registrados para la gripe aviar altamente patógena H5N8 2018. La vacuna con código nº 4 no fue potente para la gripe aviar altamente patógena de 2018 o de 2020. Por consiguiente, se recomendó actualizar la cepa de la vacuna de acuerdo con las condiciones epidemiológicas y utilizar el aislamiento de la cepa circulante predominante en la prueba de reto(AU)

Progress in research of influenza vaccination in pregnant women / 中华流行病学杂志

Influenza is an acute respiratory infectious disease caused by influenza virus. Pregnancy is associated with physiologic and immunological changes that may increase the risk for influenza virus infection and influenza-related complications. Influenza vaccination is the most effective way to prevent influenza virus infection. WHO and many countries have classified pregnant women as a priority population for influenza vaccination, however, there are still many challenges for promoting influenza vaccination in pregnant women in China, influenza vaccination coverage in pregnant women remains low and some influenza vaccine package inserts list pregnancy as an absolute contraindication. In this paper, we summarize the research progress in the effects of influenza infection and influenza vaccination during pregnancy both at home and abroad, then discuss the strategies to promote influenza vaccination in pregnancy for the purpose of providing reference for the related research and policy development in China.

Consideration on the usage of full-dose influenza vaccine for the infants aged 6-35 months old / 中华预防医学杂志

Seasonal influenza has a high disease burden, and children infected with influenza are prone to multiple complications. Influenza vaccination is effective in preventing infection and reducing risks of severe diseases and complications. Influenza vaccines are trivalent and quadrivalent, depending on the components of the vaccine. According to the hemagglutinin content, it can be divided into full dose and half dose of influenza vaccine for children. The findings from clinical trials and real-world studies suggested, the full-dose influenza vaccine as in adults has the same safety profile and higher immunogenicity in children aged 6 to 35 months. The application of full-dose influenza vaccine in children aged 6 to 35 months can greatly improve the flexibility and convenience of vaccination, and help reduce the workload in the process.

Research progress of influenza vaccination, pneumococcal vaccination and COVID-19 vaccination among cancer patients / 中华预防医学杂志

This article reviews the relevant studies on the efficacy and safety of influenza, pneumococcal and COVID-19 vaccination among tumor patients worldwide in recent years. By combing and analyzing the retrieved literature, the results show that influenza and pneumococcal vaccination can significantly reduce the morbidity and hospitalization rate of infectious diseases in tumor patients, reduce the risk of cardiovascular events and death, and significantly improve survival prognosis. COVID-19 vaccination can also protect tumor patients, especially those who have completed full dose vaccination. Authoritative guidelines and consensuses worldwide all recommend that tumor patients receive influenza, pneumococcal and COVID-19 vaccines. We should carry out relevant researches, as well as take effective measures to strengthen patient education, so that tumor patients can fully experience the health protection brought by the vaccine to this specific group.

Assessing the impact of educational methods on influenza vaccine uptake and patient knowledge and attitudes: a randomised controlled trial

INTRODUCTION@#Although influenza vaccination reduces rates of pneumonia, hospitalisation and mortality, influenza vaccination uptake remains low in older patients. The primary aim was to compare individualised counselling with educational pamphlets alone in improving influenza vaccination uptake. The secondary aims were to evaluate knowledge and attitudes towards influenza vaccination and factors influencing uptake.@*METHODS@#A randomised controlled study was conducted in two government polyclinics with 160 participants per arm. Patients aged 65 years and above attending for doctor consultation were recruited. All participants received an educational pamphlet on influenza vaccination. The intervention group received additional face-to-face counselling. Participants filled a pre- and postintervention questionnaire assessing knowledge of influenza and attitudes towards the vaccine. Follow-up calls and verification of electronic records was done at three months to determine actual vaccine uptake.@*RESULTS@#At three months, 16 (10%) patients in the intervention group and 20 (12.5%) patients in the control group had completed influenza vaccination (P = 0.48). Factors positively associated with vaccine uptake were willingness to receive vaccination immediately after intervention (adjusted odds ratio [OR] 12.15, 95% confidence interval [CI] 4.42-33.38), and male gender (adjusted OR 2.96, 95% CI 1.23-7.12). Individualised counselling was more effective in improving knowledge (P < 0.01). Overall knowledge scores did not influence actual vaccine uptake rates. (adjusted OR 1.10 [0.90-1.3]).@*CONCLUSION@#Both arms of patient education increased uptake of influenza vaccination. Individualised counselling was not superior to pamphlets alone in improving uptake. Performing vaccination at the initial point of contact improves actual uptake rates.

Doenças crônicas em idosos e vacinação contra a influenza: orientação dos profissionais de saúde e o papel da mídia / Chronic diseases in older people and influenza vaccination: the guidance of health professionals and the role of the media / Enfermedades crónicas em adultos mayores y vacunación contra la influenza: la orientación de los profesionales de la salud y el papel de los medios de comunicación

Introdução: As informações sobre a presença de doenças crônicas nos idosos não são registradas durante as campanhas de vacinação contra influenza, o que dificulta sua identificação (proporção) nos idosos vacinados. Objetivo: Descrever a prevalência de doenças crônicas autorreferidas em idosos vacinados contra a influenza; verificar a influência da mídia na decisão de tomar a vacina; e se recebeu orientações sobre a importância dela, segundo o tipo de profissional de saúde. Métodos: Estudo transversal descritivo, com dados coletados por meio de entrevistas com idosos vacinados contra influenza (n=798) em um Centro de Saúde de Campinas (SP) em 2019. Resultados: Na amostra estudada, a maioria eram mulheres (58,0%), indivíduos com ensino médio completo ou ensino superior (53,0%) e com plano de saúde (72,3%). As doenças mais prevalentes foram hipertensão arterial (56,9%; intervalo de confiança ­ IC95% 53,4­60,3), diabetes(24,7%; IC95% 21,8­27,8), doenças cardíacas (13,6%; IC95% 11,4­16,2) e respiratórias (5,6%; IC95% 4,2­7,5). A maioria (58,0%) considerou que a mídia influenciou sua decisão de tomar a vacina. Receberam orientações sobre a importância da vacinação 21,1% dos idosos, fornecidas principalmente por médicos/as (67,4%), enfermeiros/as (18,2%) e agentes de saúde (7,0%). Conclusões: A investigação mostrou que as principais doenças referidas pelos idosos vacinados foram hipertensão arterial, diabetes, cardiopatias e doenças respiratórias. A orientação de profissionais da saúde foi pouco relatada pelos idosos e a maioria referiu influência da mídia na decisão de vacinar-se. Ressaltam-se a necessidade e a relevância de investir em estratégias de comunicação em saúde, a fim de esclarecer a população sobre a importância da vacinação contra a influenza para as pessoas idosas e com doenças crônicas.

Introduction: Information on the presence of chronic diseases in older adults is not registered during influenza vaccination campaigns, which hinders its identification (proportion) in vaccinated older people. Objective: To describe the prevalence of self-reported chronic diseases in older people vaccinated against influenza; to verify the influence of the media in the decision to receive the vaccine; and if older adults received guidance on the importance of the vaccine, according to the type of health professional. Methods: This is a descriptive, cross-sectional study with data collected via interviews with older people vaccinated against influenza (n=798) in a Health Center of Campinas (state of São Paulo, Brazil) in 2019. Results: Most individuals were women (58.0%), with high school degree or higher education (53.0%), and with health insurance (72.3%). The most prevalent diseases were hypertension (56.9%; 95%CI 53.4-60.3), diabetes (24.7%; 95%CI 21.8-27.8), heart diseases (13.6%; 95%CI 11.4-16.2), and respiratory diseases (5.6%; 95%CI 4.2-7.5). A maioria (58,0%) considerou que a mídia influenciou sua decisão de tomar a vacina. The majority (58.0%) considered that the media influenced the decision to have the vaccine; 21.1% of the older adults received guidance on the importance of vaccination, mainly provided by physicians (67.4%), nurses (18.2%), and health workers (7.0%). Conclusions: The main diseases reported by the vaccinated older adults were hypertension, diabetes, heart diseases, and respiratory diseases. The guidance of health professionals was little reported, and most older people mentioned that the media influenced the decision to be vaccinated. The authors emphasize the need and relevance of investing in health communication strategies to inform the population about the importance of influenza vaccination for older adults and those with chronic diseases.

Introducción: Información sobre la presencia de enfermedades en los adultos mayores no se registra durante las campañas de vacunación antigripal, lo que dificulta la identificación (proporción) en los adultos mayores. Objetivo: Describir la prevalencia de enfermedades crónicas en adultos mayores vacunados contra la influenza; verificar la influencia de los medios de comunicación en la decisión de vacunarse y; orientación sobre la importancia de la vacuna, según los profesionales de la salud. Métodos: Estudio descriptivo transversal con adultos mayores vacunados contra la influenza (n=798) en un Centro de Salud de Campinas/SP en 2019. Resultados: La mayoría era mujeres (58,0%), individuos con educación secundaria completa o superior (53,0%) y seguro de salud (72,3%). Las principales enfermedades fueron hipertensión arterial (56,9%; IC95% 53,4-60,3), diabetes (24,7%; IC95% 21,8-27,8), cardiopatías (13,6%; IC95% 11,4-16,2) y enfermedades respiratorias (5,6%; IC95% 4,2-7,5). La mayoría (58,0%) consideró que los medios de comunicación influyeron en la decisión de recibir la vacuna. El 21,1% de los adultos mayores recibió orientación sobre la importancia de la vacunación, proporcionada principalmente por médicos (67,4%), enfermeras (18,2%), agentes comunitarios de salud (7,0%). Conclusiones: La investigación ha demonstrado que las principales enfermedades reportadas fueron hipertensión, diabetes, enfermedades del corazón y respiratorias. La orientación de los profesionales de la salud fue poco mencionada y la mayoría refirió que los medios de comunicación influyeron en la decisión de vacunarse. Se enfatiza la necesidad y relevancia de invertir en estrategias de comunicación en salud con el fin de aclararle a la población sobre la importancia de la vacunación para los adultos mayores y las personas con enfermedades crónicas.

Vacinação contra influenza em idosos no contexto da pandemia da COVID-19: situação atual e perspectivas futuras / Influenza vaccination in older adults in the context of the COVID-19 pandemic: current situation and future perspectives / Vacunación antigripal en ancianos en el contexto de la pandemia COVID-19: situación actual y perspectivas de futuro

A vacinação anual contra influenza em idosos tem sido exitosa desde a sua implementação no Brasil, atingindo as metas de cobertura vacinal. Com o surgimento da COVID-19, observaram-se dois cenários. Em 2020, a cobertura vacinal contra influenza nos idosos atingiu 120,7%; e em 2021, com o advento da vacina contra a COVID-19 e a vacinação no mesmo período da campanha de influenza, a cobertura foi de 70,9% em idosos. Em 2022, a campanha contra esta doença também foi concomitante com a aplicação das doses de reforço contra a COVID-19. Até agosto de 2022, a cobertura vacinal da influenza foi 70,2% em idosos, apesar da sua relevância para a proteção contra o subtipo A (H3N2). O texto discute estratégias para o aumento da cobertura vacinal contra influenza em idosos nos próximos anos, visando ao fortalecimento da Atenção Primária à Saúde para a sensibilização dos idosos e a adoção de estratégias de vacinação extramuros.

Annual influenza vaccination in older adults has been successful since its implementation in Brazil, reaching vaccination coverage targets. With the emergence of COVID-19, two scenarios were observed. In 2020, influenza vaccination coverage in older adults reached 120.7%; and in 2021, with the advent of the vaccine against COVID-19 and vaccination in the same period of the influenza campaign, coverage was 70.9% in the older group. In 2022, the influenza campaign was also concomitant with the application of booster doses against COVID-19. Until August 2022, influenza vaccination coverage was 70.2% in older adults, despite its relevance for protection against subtype A (H3N2). The text discusses some strategies to increase influenza vaccination coverage in older adults in the next years, aiming to strengthen Primary Health Care to raise awareness among the older adults and adopt extramural vaccination strategies.

La vacunación anual contra la influenza en ancianos ha sido existosa desde su implementación en Brasil, alcanzando las metas de cobertura de vacunación. Con la aparición del COVID-19, fue posible observar dos escenarios. En 2020, la cobertura de vacunación contra la influenza en adultos mayores alcanzó el 120,7%; y en 2021, con el advenimiento de la vacuna contra la COVID-19 y la vacunación en el mismo período de la campaña de influenza, la cobertura fue del 70,9% en los adultos mayores. En 2022, la campaña de influenza también fue concomitante con la aplicación de dosis de refuerzo contra el COVID-19. Hasta agosto de 2022, la cobertura de vacunación contra la influenza era del 70,2% en adultos mayores, a pesar de su relevancia para la protección contra el subtipo A (H3N2). El texto discute algunas estrategias para aumentar la cobertura de vacunación antigripal en ancianos en los próximos años, con el objetivo de fortalecer la Atención Primaria de Salud para sensibilizar a los ancianos y adoptar estrategias de vacunación extramuros.

Association between willingness to receive the COVID-19 vaccine and sources of health information among Japanese workers: a cohort study

BACKGROUND@#It is important to achieve herd immunity by vaccinating as many people as possible to end the COVID-19 pandemic. We investigated the relationship between willingness to receive vaccination and sources of health information among those who did not want to be vaccinated against COVID-19.@*METHODS@#This prospective cohort study collected data using a self-administered questionnaire survey. The baseline survey was conducted during December 22-25, 2020, and the follow-up survey during February 18-19, 2021. Participants were aged 20-65 years and worked at the time of the baseline survey (N = 33,087). After excluding 6,051 invalid responses, we included responses from 27,036 participants at baseline. In total, 19,941 people responded to the follow-up survey (74% follow-up rate). We excluded 7,415 participants who answered "yes" to the question "If a COVID-19 vaccine becomes available, would you like to get it?" in the baseline survey. We finally analyzed 12,526 participants.@*RESULTS@#The odds ratio for change in willingness to be vaccinated from "no" to "yes" differed by source of health information. Compared with workers that used TV as a source of information, significantly fewer people who reported getting information from the Internet and friends/colleagues were willing to get the vaccine.@*CONCLUSIONS@#It is important to approach workers who do not watch TV when implementing workplace vaccination programs. It is likely that willingness to be vaccinated can be increased through an active company policy whereby the top management recommend vaccination, coupled with an individual approach by occupational health professionals.@*TRIAL REGISTRATION@#Not applicable.

Expression of influenza B virus hemagglutinin and its immunogenicity determination / 生物工程学报

Influenza B virus is one of the causes for seasonal influenza, which can account for serious illness or even death in some cases. We tested the expression of extracellular domain of hemagglutinin (HA-ecto) of influenza B viruses in mammalian cells, and then determined the immunogenicity of HA-ecto in mice. The gene sequence encoding influenza B virus HA-ecto, foldon sequence, and HIS tag was optimized and inserted into pCAGGS vector. The opening reading frame (ORF) of neuraminidase was also cloned into pCAGGS. The pCAGGS-HA-ecto and pCAGGS-NA were co-transfected into 293T cells using linear polyethylenimine. Cell supernatant after transfection was collected after 96 h, and the secreted trimmeric HA-ecto protein was purified by nickel ion affinity chromatography and size exclusion chromatography. Subsequently, the mice were immunized with HA-ecto protein, and the corresponding antibody titers were detected by ELISA and hemagglutination inhibition (HAI) assays. The results showed that soluble trimeric HA-ecto protein could be obtained using mammalian cell expression system. Moreover, trimeric HA-ecto protein, in combination with the adjuvant, induced high levels of ELISA and HAI antibodies against homogenous and heterologous antigens in mice. Thus, the soluble HA-ecto protein expressed in mammalian cells could be used as a recombinant subunit vaccine candidate for influenza B virus.

A broadly neutralizing human monoclonal antibody against the hemagglutinin of avian influenza virus H7N9 / 中华医学杂志(英文版)

BACKGROUND@#The new emerging avian influenza A H7N9 virus, causing severe human infection with a mortality rate of around 41%. This study aims to provide a novel treatment option for the prevention and control of H7N9.@*METHODS@#H7 hemagglutinin (HA)-specific B cells were isolated from peripheral blood plasma cells of the patients previously infected by H7N9 in Jiangsu Province, China. The human monoclonal antibodies (mAbs) were generated by amplification and cloning of these HA-specific B cells. First, all human mAbs were screened for binding activity by enzyme-linked immunosorbent assay. Then, those mAbs, exhibiting potent affinity to recognize H7 HAs were further evaluated by hemagglutination-inhibiting (HAI) and microneutralization in vitro assays. Finally, the lead mAb candidate was selected and tested against the lethal challenge of the H7N9 virus using murine models.@*RESULTS@#The mAb 6-137 was able to recognize a panel of H7 HAs with high affinity but not HA of other subtypes, including H1N1 and H3N2. The mAb 6-137 can efficiently inhibit the HA activity in the inactivated H7N9 virus and neutralize 100 tissue culture infectious dose 50 (TCID50) of H7N9 virus (influenza A/Nanjing/1/2013) in vitro, with neutralizing activity as low as 78 ng/mL. In addition, the mAb 6-137 protected the mice against the lethal challenge of H7N9 prophylactically and therapeutically.@*CONCLUSION@#The mAb 6-137 could be an effective antibody as a prophylactic or therapeutic biological treatment for the H7N9 exposure or infection.

Progress in research of safety, efficiency and vaccination status of influenza vaccine in populations at high risk / 中华流行病学杂志

This paper reviews the domestic and foreign studies published in 2020 on the application of influenza vaccine in populations at high risk. The importance of influenza vaccination in population at high risk has been proved by larger sample, multicentre, high-quality evidence-based studies. Influenza vaccination is the most cost-effective measure to prevent influenza. However, the coverage rate of influenza vaccine is very low in China, it is necessary to strengthen the health education to promote influenza vaccination in different populations. It is recommended to give influenza vaccination to the population in whom influenza vaccination has been proven safe and effective before influenza season. Research of the safety, efficiency and cost-effectiveness of influenza vaccine should be accelerated for the populations in whom such data are lacking or insufficient.

Analysis on vaccination willingness and related factors of influenza, pneumonia, and herpes zoster vaccine among people over 50 years old in Minhang district of Shanghai / 中华预防医学杂志

Objective: To determine the knowledge of influenza, pneumonia, herpes zoster and related vaccines, willingness to vaccinate under multiple payment scenarios, and corresponding risk factors among people over 50 years old in Minhang District of Shanghai. Methods: A total of 1 672 respondents aged 50-69 from 13 communities/towns in Minhang district of Shanghai were included in this study using a stratified random sampling strategy on December 2020. The knowledge of influenza, pneumonia, herpes zoster and vaccines was investigated using a questionnaire, and the differences in the willingness under multiple payment scenarios were determined using chi-square test. The consistency in the willingness under multiple payment scenarios was compared using Cohen's Kappa and the risk factors of the willingness was determined using ordinal logistic regression. Results: The average age of 1 672 respondents was (60.48±5.96) years old, including 777 (46.47%) males and 895 (53.53%) females. A total of 1 350 subjects (80.74%) had local household registration in Shanghai. The proportion of the willingness to vaccinate for themselves, spouses, and parents under any payment scenario was determined to be 80.6% (influenza vaccine), 81.5% (pneumonia vaccine), and 74.0% (herpes zoster vaccine). The willingness to vaccinate against influenza and pneumonia under multiple payment scenarios remained stable (Kappa value ≥0.6), while that against herpes zoster infection was inconsistent (Kappa value ≤0.35). Logistic regression analysis showed that respondents who had higher knowledge of influenza and influenza vaccine [OR (95%CI): 1.111 (1.054-1.170), 1.182 (1.126-1.240), respectively], aged 50-59 [1.305 (1.085-1.531)] and local household registration in Shanghai [1.372 (1.079-1.721)] had higher willingness to vaccinate against influenza, while males had lower willingness [0.733 (0.551-0.910)]. Respondents who had higher knowledge of pneumonia and pneumonia vaccine [OR (95%CI): 1.837 (1.152-2.517), 2.217 (1.541-2.893), respectively] had higher willingness to receive pneumonia vaccine. Respondents aged 50-59 [1.327 (1.059-1.537)] and with local household registration in Shanghai [2.497 (1.417-4.400)] were more likely to be vaccinated against herpes zoster, while those with middle school degree or below [0.664 (0.396-0.992)] and high school degree [0.559 (0.324-0.964)] were less likely to be vaccinated. Conclusion: Among people aged over 50 years old in Minhang district of Shanghai, the willingness to vaccinate for themselves, spouses, and parents against influenza, pneumonia and herpes zoster infection is quite different under multiple payment scenarios, especially for herpes zoster vaccine.

Consideration on implementation of co-administration of Seasonal Influenza and COVID-19 vaccines during pandemic in China / 中华预防医学杂志

Influenza is an infectious respiratory disease caused by the influenza viruses. Older people, infants and people with underlying medical conditions could have a higher risk of severe influenza symptoms and complications. The co-infection of Coronavirus Diseases 2019 (COVID-19) with influenza viruses could lead to the complication of prevention, diagnosis, control, treatment, and recovery of COVID-19. Influenza vaccine and COVID-19 vaccine overlapped in target populations, vaccination time, and inoculation units. Although there was insufficient evidence on the immunogenicity and safety of co-administration of influenza vaccine and COVID-19 vaccine, World Health Organization and some countries recommended co-administration of inactivated influenza vaccine and COVID-19 vaccine. This review summarized domestic and international vaccination policies and research progress, and put forward corresponding suggestions in order to provide scientific support for the formulation of vaccination strategy on seasonal influenza vaccine and COVID-19 vaccine.

Trend analysis of influenza vaccination among hospitalized elderly people in Beijing, 2013-2019 / 北京大学学报(医学版)

OBJECTIVE@#To analyze the influenza vaccination trend of hospitalized elderly people (≥ 60 years old) in Beijing from 2013 to 2019.@*METHODS@#The influenza vaccination status and hospitalization information of elderly people were extracted from the Beijing Elderly Influenza Vaccination database (2013-2019) and the Beijing Urban Employee Basic Medical Insurance database (2013-2019), se-parately. The influenza vaccine coverage rates and annual percentage change were calculated to compare the vaccination trends of elderly people hospitalized due to different diseases. The subjects in 2018-2019 influenza season were divided into different groups according to demographic status, health conditions and hospitalization outcomes to describe and compare the distribution of influenza vaccination rates.@*RESULTS@#The influenza vaccine coverage rates among the elderly people hospitalized due to cardiovascular diseases, cerebrovascular diseases, respiratory diseases or diabetes mellitus were 14.6%, 13.4%, 13.4% and 11.8%, respectively. The influenza vaccination rate among those hospitalized for cardiovascular diseases remained the highest across six influenza seasons and those hospitalized for diabetes mellitus remained the lowest. The largest annual decline of influenza vaccine coverage rate was observed among the hospitalized elderly due to diabetes mellitus (-7.85%). The distribution of vaccinated population was significantly associated with age, gender, hospitalization outcome and comorbidities among the hospitalized elderly people with specific diseases in 2018-2019. Among the elderly people hospitalized due to four different diseases, the vaccination rate of the patients aged 70-79 years was higher than that of the other age groups and that of the patients aged 60-69 years was the lowest. Among the elderly people hospitalized due to respiratory diseases, the vaccination rate of men was higher than that of women, while the situation reversed among the elderly people hospitalized due to cardiovascular diseases and diabetes mellitus. Vaccination rates decreased among the older adults with poor hospitalization outcomes. Among the elderly people hospitalized due to diabetes mellitus, those with 0 comorbidity had the lowest vaccination rate (7.9%).@*CONCLUSION@#The trend of influenza vaccine coverage rates among the elderly people in Beijing from 2013 to 2019 was downward. We should pay more attention to influenza vaccination in elderly people with diabetes mellitus and aged 60-69 years, and carry out more research on the protective effects of influenza vaccine to promote influenza vaccine coverage among people with chronic diseases.

Barriers and facilitators to influenza vaccination observed by officers of national immunization programs in South America countries with contrasting coverage rates / Barreras y facilitadores de la vacuna contra la gripe observados por funcionarios de los programas nacionales de inmunización en países de Suramérica con niveles de cobertura contrastantes / Barreiras e facilitadores da vacinação contra influenza observados por funcionários dos programas nacionais de imunização em países Sul-Americanos com diferentes níveis de cobertura

Influenza is a severe, vaccine-preventable disease. Vaccination programs across Latin American countries show contrasting coverage rates, from 29% in Paraguay to 89% in Brazil. This study explores how national influenza vaccination programs in the chosen South American countries address vaccine confidence and convenience, as well as complacency toward the disease. Barriers and facilitators to influenza vaccination programs in their relation to vaccine hesitancy were observed by documentary analysis and interviews with 38 national immunization program officers in high- (Brazil and Chile) and low-performing (Paraguay, Peru, and Uruguay) countries. Influenza vaccination policies, financing, purchasing, coordination, and accessibility are considered good or acceptable. National communication strategies focus on vaccine availability during campaigns. In Chile, Paraguay, and Uruguay, anti-vaccine propaganda was mentioned as a problem. Programming and implementation face human resource shortages across most countries. Statistical information, health information systems, and nominal risk-group records are available, with limitations in Peru and Paraguay. Health promotion, supervision, monitoring, and evaluation are perceived as opportunities to address confidence and complacency. Influenza vaccination programs identify and act on most barriers and facilitators affecting influenza vaccine hesitancy via supply-side strategies which mostly address vaccine convenience. Confidence and complacency are insufficiently addressed, except for Uruguay. Programs have the opportunity to develop integral supply and demand-side approaches.

La gripe es una enfermedad grave, prevenible mediante vacunas con sus correspondientes programas en países latinoamericanos, informando sobre tasas contrastadas de cobertura, desde el 29% en Paraguay al 89% en Brasil. Este artículo investiga cómo los programas nacionales contra la gripe en países seleccionados de Suramérica abordan la confianza en la vacuna y su conveniencia, así como también la complacencia hacia la enfermedad. Las barreras y facilitadores del programa de vacunación de la gripe, en su relación con la vacilación hacia la vacuna, se observaron mediante análisis documental y entrevistas a 38 a cargo de los programas nacionales de inmunización en países con alto (Brasil y Chile) y bajo desempeño (Paraguay, Perú y Uruguay). Políticas de vacunación contra la gripe, financiamiento, compras coordinación y accesibilidad fueron consideradas como buenas o aceptables. Las estrategias nacionales de comunicación se centran en la disponibilidad de la vacuna durante las campañas. En Chile, Paraguay y Uruguay la propaganda antivacunas fue mencionada como un problema. La planificación e implementación enfrentan escasez de recursos humanos en la mayoría de países a través de la mayoría de países. Los sistemas de información en salud, estadísticas y registros nominales por grupos de riesgo se encuentran disponibles con limitaciones en Perú y Paraguay. La promoción de la salud, supervisión, monitoreo y evaluación son percibidos como oportunidades para abordar la confianza y complacencia. Los programas de vacunación contra la gripe actúan principalmente sobre las barreras y facilitadores que afectan la vacilación a vacunarse mediante estrategias del lado de la demanda, las cuales en su mayor parte van dirigidas a contrarestar la conveniencia. La confianza y complacencia son insuficientemente abordadas en todos los países, excepto en Uruguay. Los programas tienen la oportunidad de desarrollar estrategias que aborden tanto el lado de la oferta como de la demanda.

A influenza é uma doença grave, imunoprevenível, para a qual os programas de vacinação nos países latino-americanos apresentam taxas de cobertura contrastantes, desde 29% no Paraguai até 89% no Brasil. O artigo explora de que maneira os programas nacionais de influenza em países selecionados da América do Sul lidam com a confiança e a conveniência da vacina, assim como, a acomodação em relação à doença. As barreiras e facilitadores dos programas de vacinação contra influenza foram observados em relação à hesitação vacinal, através de análise documental e entrevistas com 38 autoridades de programas nacionais de imunização em países com desempenho alto (Brasil e Chile) e baixo (Paraguai, Peru e Uruguai). As políticas de vacinação contra influenza, financiamento da compra de vacinas, coordenação e acessibilidade são consideradas boas ou aceitáveis. As estratégias nacionais de comunicação estão concentradas na disponibilidade durante campanhas. No Chile, Paraguai e Uruguay, a propaganda antivacina foi mencionada enquanto problema. A programação e a implementação enfrentam escassez de recursos humanos na maioria dos países. Dados estatísticos, sistemas de informação em saúde e registros nominais de grupos de risco estão disponíveis, com limitações no Peru e no Paraguai. A promoção da saúde, supervisão, monitoramento e avaliação foram percebidas como oportunidades para tratar da confiança e da acomodação. Os programas de vacinação contra influenza identificam e agem sobre a maioria das barreiras e facilitadores que afetam a hesitação vacinal através de estratégias do lado da oferta, tratando principalmente da conveniência da vacina. A confiança e a acomodação não são tratadas de maneira suficiente, com exceção notável do Uruguai. Os programas têm a oportunidade de desenvolver abordagens que integram os lados da oferta e da procura.

Mortalidade por COVID-19 no Brasil em distintos grupos etários: diferenciais entre taxas extremas de 2021 e 2022 / COVID-19 mortality in Brazil in different age groups: differentials between extreme rates in 2021 and 2022 / Mortalidad por COVID-19 en Brasil en diferentes grupos de edad: diferenciales entre tasas extremas del 2021 y del 2022

Avaliar a trajetória das taxas de mortalidade por COVID-19 no Brasil e comparar as taxas extremas de 2022 e de 2021, em distintos grupos etários. Estudo ecológico com óbitos por síndrome respiratória aguda grave por COVID-19, tendo o Brasil como unidade de análise. Os dados foram obtidos do Sistema de Informação da Vigilância Epidemiológica da Gripe. Foram avaliados os óbitos no período de 10 de janeiro de 2021 a 12 de fevereiro de 2022, agrupado em Semanas Epidemiológicas (SE). A análise dos dados foi conduzida no software R, utilizando modelos Poisson para estimar as taxas de mortalidade. O nível de significância estatística foi 5%. Foram avaliados 408.180 óbitos, sendo 0,34% de indivíduos menores de18 anos e 64,6% daqueles com 60 anos e mais. De um lado, nas faixas etárias de 0-1, 2-4 e 5-11 anos, observaram-se maiores taxas de mortalidade nas SE 4-6/2022, em comparação às maiores de 2021. De outro, nos indivíduos de 12-17 anos, estimou-se taxa inferior no grupo de SE 4-6/2022, em comparação ao grupo de SE 11-13 de 2021, com razão de mortalidade 0,60 (IC95%: 0,38-0,94). Detectaram-se padrões opostos na mortalidade por COVID-19 no Brasil entre crianças e indivíduos incluídos na campanha nacional de vacinação. Entre os primeiros, observaram-se taxas de mortalidade iguais ou piores do que em fases anteriores da epidemia, contrapondo-se ao registro de queda consistente e forte dos últimos, reforçando a efetividade da vacina contra COVID-19.

This ecological study evaluated the trajectory of COVID-19 mortality rates in Brazil and compared the extreme rates of 2022 and 2021, in different age groups. Data on deaths due to severe acute respiratory syndrome by COVID-19 were obtained from the Influenza Epidemiological Surveillance Information System. Deaths were evaluated from January 10, 2021 to February 12, 2022, grouped into Epidemiological Weeks (EW). Data analysis was conducted in the R software, using Poisson models to estimate mortality rates. Statistical significance level was set at 5%. A total of 408,180 deaths were evaluated, 0.34% of whom were under 18 years old, and 64.6% of whom were 60 years old and over. On the one hand, in the 0-1, 2-4 and 5-11 age groups, higher mortality rates were observed in EW 4-6/2022, compared to the higher ones in 2021. On the other, in the 12-17 age group, a lower rate was estimated in the EW 4-6/2022 group compared to the EW 11-13 group in 2021, with a mortality ratio of 0.60 (95%CI: 0.38-0.94). Opposing patterns were detected in COVID-19 mortality in Brazil among children and individuals included in the national vaccination campaign. Among the former, mortality rates equal to or worse than in previous phases of the epidemic were observed, contrasting with the consistent and strong decline registered in the latter, reinforcing the effectiveness of COVID-19 vaccines.

Los objetivos fueron evaluar la trayectoria de las tasas de mortalidad por COVID-19 en Brasil y comparar las tasas extremas del 2022 y del 2021, en diferentes grupos de edad. Estudio ecológico con muertes por síndrome respiratorio agudo Severo por COVID-19, teniendo a Brasil como unidad de análisis. Los datos se obtuvieron del Sistema de Información de Vigilancia Epidemiológica de la Gripe. Se evaluaron las defunciones del 10 de enero del 2021 al 12 de febrero del 2022, agrupadas en Semanas Epidemiológicas (SE). El análisis de datos se realizó en el software R, utilizando modelos Poisson para estimar las tasas de mortalidad. El nivel de significancia estadística fue del 5%. Se evaluaron un total de 408.180 defunciones, el 0,34% fue de individuos menores de 18 años y el 64,6% fue de individuos con 60 años o más. Por una parte, en los rangos de edad 0-1, 2-4 y 5-11 se observaron mayores tasas de mortalidad en SE 4-6/2022, en comparación con las más altas del 2021. Por otra parte, en los individuos de 12-17 años se estimó una tasa inferior en el grupo SE 4-6/2022, en comparación con el grupo de SE 11-13 del 2021, con una razón de mortalidad de 0,60 (IC95%: 0,38-0,94). Se detectaron estándares opuestos en la mortalidad por COVID-19 en Brasil entre niños e individuos incluidos en la campaña nacional de vacunación. Entre los primeros, se observaron tasas de mortalidad iguales o peores que en etapas anteriores de la epidemia, en contraste con el registro de una reducción consistente y fuerte de los últimos, lo que reforzó la efectividad de la vacuna contra la COVID-19.